Evidence map›Paper›PMID 38807129›Full record

ReviewRespiratory research2024

Unveiling the metabolic landscape of pulmonary hypertension: insights from metabolomics.

Huixue Ba, Yingfan Guo, Yujie Jiang, Ying Li, Xuejing Dai, Yuan Liu, Xiaohui Li

Abstract readReview
In one paragraph

Review in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Mechanical Activation of cPLA2 Impedes Fatty Acid β-Oxidation in Vein Grafts.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huixue Ba *Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Yingfan Guo *Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Yujie Jiang *Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Ying LiDepartment of Health Management, The Third Xiangya Hospital of Central South University, Changsha, China.
Xuejing DaiDepartment of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Yuan LiuDepartment of Anesthesiology, The Second Xiangya Hospital of Central South University, Changsha, China. 218202146@csu.edu.cn.
Xiaohui LiDepartment of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China. xiaohuili@csu.edu.cn.

Funding

Ying Li No: 81973324 and No: YX202002
6 · The paper itself

Abstract

Pulmonary hypertension (PH) is regarded as cardiovascular disease with an extremely poor prognosis, primarily due to irreversible vascular remodeling. Despite decades of research progress, the absence of definitive curative therapies remains a critical challenge, leading to high mortality rates. Recent studies have shown that serious metabolic disorders generally exist in PH animal models and patients of PH, which may be the cause or results of the disease. It is imperative for future research to identify critical biomarkers of metabolic dysfunction in PH pathophysiology and to uncover metabolic targets that could enhance diagnostic and therapeutic strategies. Metabolomics offers a powerful tool for the comprehensive qualitative and quantitative analysis of metabolites within specific organisms or cells. On the basis of the findings of the metabolomics research on PH, this review summarizes the latest research progress on metabolic pathways involved in processes such as amino acid metabolism, carbohydrate metabolism, lipid metabolism, and nucleotide metabolism in the context of PH.

Indexed as

Hypertension, PulmonaryMetabolomicsAnimalsHumansLipid MetabolismAmino acid metabolismBiomarkerCarbohydrate metabolismLipid metabolismMetabolomicsNucleotide metabolismPulmonary hypertension

Identifiers

PMID38807129
PMCPMC11131231

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.